MedTrace Logo

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

NCT05733598 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-02

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC.

Conditions

Interventions

BIOLOGICAL

RP2

Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.

BIOLOGICAL

Bevacizumab

Anti-VEGF therapy.

BIOLOGICAL

Atezolizumab

Anti-PD-L1 monoclonal antibody.

BIOLOGICAL

Durvalumab

Anti-PD-L1 monoclonal antibody

BIOLOGICAL

RP2 Monotherapy

Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.

Sponsors & Collaborators

  • Replimune Inc.

    lead INDUSTRY

Principal Investigators

  • Gary Vanasse, MD · Replimune Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2027-12-01
Completion
2028-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05733598 on ClinicalTrials.gov